PARA023
Prometheus Biosciences, Inc.,Takeda
['ibd', 'takeda']
 shows week 12 results of anti tl1a for uc. good delta but note very low placebo rates. genetic marker to identify better responders suggests possible effect but it does not stand out significantly at this time point. #ecco2023 
Gastroenterologist Scientist MD PhD #IBD #Crohnsdisease #colitis #genetics #microbiome #diversity #nutrition. Founder @TorDigHealthIns https://t.co/P3JYSG9yiT